RxDoctor Payments Data

Homer Beavers, MD

Internal Medicine · Russellville, ARNPI 1982660742

Payments from drug & device makers

$365in general payments, 2019–2025

Across 23 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$79
  • Novo Nordisk$73
  • Boehringer Ingelheim$50
  • Lilly USA, LLC$43
  • Amgen$35
  • AbbVie$24
  • plus $62 from 4 others

What the payments were for

  • Food & beverage$365100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$365 in reported general payments places this provider in the 55th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$266,502
Medicare patients
640
Services billed
9,183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide188$207,817
MounjaroTirzepatide76$116,312
EliquisApixaban121$102,703
Humira(Cf) PenAdalimumab12$81,739
XareltoRivaroxaban60$61,558
FarxigaDapagliflozin Propanediol51$50,996
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$47,475
LinzessLinaclotide45$32,614
TrulicityDulaglutide35$32,452
JanuviaSitagliptin Phosphate26$21,859
MyrbetriqMirabegron30$20,174
MultaqDronedarone Hcl12$18,598
JardianceEmpagliflozin16$18,535
GemtesaVibegron32$17,530
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen603$13,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$73$207,817188 claims
Lilly USA, LLCMounjaro, Trulicity$43$148,764111 claims
PfizerEliquis$79$102,703121 claims
AstraZenecaFarxiga, Brilinta, Symbicort$17$70,01694 claims
GSKTrelegy Ellipta, Breo Ellipta$15$54,22967 claims
AbbVieLinzess, Namzaric, Synthroid$24$42,104115 claims
Boehringer IngelheimJardiance$50$18,53516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Russellville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →